Identification of fumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics

Riccardo Riccardi, Piergiorgio Modena, Elena Lualdi, Federica Facchinetti, Joris Veltman, James F. Reid, Simone Minardi, Irene Janssen, Felice Giangaspero, Marco Forni, Gaetano Finocchiaro, Lorenzo Genitori, Flavio Giordano, Eric F.P.M. Schoenmakers, Maura Massimino, Gabriella Sozzi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

170 Citazioni (Scopus)

Abstract

PURPOSE: To delineate clinically relevant molecular signatures of intracranial ependymoma. MATERIALS AND METHODS: We analyzed 24 primary intracranial ependymomas. For genomic profiling, microarray-based comparative genomic hybridization (CGH) was used and results were validated by fluorescent in situ hybridization and loss of heterozygosity mapping. We performed gene expression profiling using microarrays, real-time quantitative reverse transcriptase polymerase chain reaction, and methylation analysis of selected genes. We applied class comparison analyses to compare both genomic and expression profiling data with clinical characteristics. RESULTS: A variable number of genomic imbalances were detected by array CGH, revealing multiple regions of recurrent gain (including 2q23, 7p21, 12p, 13q21.1, and 20p12) and loss (including 5q31, 6q26, 7q36, 15q21.1, 16q24, 17p13.3, 19p13.2, and 22q13.3). An ependymoma-specific gene expression signature was characterized by the concurrent abnormal expression of developmental and differentiation pathways, including NOTCH and sonic hedgehog signaling. We identified specific differentially imbalanced genomic clones and gene expression signatures significantly associated with tumor location, patient age at disease onset, and retrospective risk for relapse. Integrated genomic and expression profiling allowed us to identify genes of which the expression is deregulated in intracranial ependymoma, such as overexpression of the putative proto-oncogene YAP1 (located at 11q22) and downregulation of the SULT4A1 gene (at 22q13.3). CONCLUSION: The present exploratory molecular profiling study allowed us to refine previously reported intervals of genomic imbalance, to identify novel restricted regions of gain and loss, and to identify molecular signatures correlating with various clinical variables. Validation of these results on independent data sets represents the next step before translation into the clinical setting.
Lingua originaleEnglish
pagine (da-a)5223-5233
Numero di pagine11
RivistaJournal of Clinical Oncology
Volume24
DOI
Stato di pubblicazionePubblicato - 2006

Keywords

  • intracranial ependymoma
  • molecular signatures

Fingerprint

Entra nei temi di ricerca di 'Identification of fumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics'. Insieme formano una fingerprint unica.

Cita questo